Diagnosis, Screening, and Early Detection of Ovarian Cancer
There is no routine screening test that has been shown to lower the risk of dying from ovarian cancer in women at average risk who have no symptoms. Because of this, diagnosis relies on a combination of clinical assessment, imaging, and laboratory testing rather than a single definitive test. Understanding how ovarian cancer is actually diagnosed — and why population-wide screening is not recommended — can help patients have more informed conversations with their care team.
Key Takeaways
- No screening test has been shown to lower the risk of dying from ovarian cancer in women at average risk who have no symptoms.
- Diagnosis relies on a combination of pelvic exam, imaging (usually transvaginal ultrasound), and blood tests such as CA-125, rather than any single test.
- An elevated CA-125 level can point toward ovarian cancer, but it can also rise with benign conditions such as endometriosis, so it is not used alone to diagnose the disease.
- A biopsy — tissue removed and examined under a microscope, usually during surgery — is what confirms an ovarian cancer diagnosis.
- Screening tests carry real risks, including false results and unnecessary follow-up procedures, which is part of why routine screening is not recommended for people without symptoms or a known higher risk.
How is Ovarian Cancer Diagnosed?
A systematic clinical process is used to diagnose ovarian cancer, starting with a review of a patient’s medical history and a pelvic exam. A pelvic exam is a hands-on check of the reproductive organs and rectum, letting a clinician feel for anything out of the ordinary in size, shape, or position, since symptoms such as pelvic discomfort or abdominal bloating tend to be subtle and easy to overlook.
Diagnosis is not based on a single test but on the combination of a clinical exam, imaging, and laboratory results, with tissue evaluation (biopsy) needed to confirm the disease. Although it is not a common cancer, ovarian cancer ranks sixth among causes of cancer death in women nationally and is the most lethal of the gynecologic cancers, which is part of why prompt, appropriate evaluation matters once symptoms or findings raise concern.
Screening Approaches and Clinical Assessment
Routine ovarian cancer screening is not recommended for people at average risk who have no symptoms. Trials that tested transvaginal ultrasound by itself, and trials that paired it with the CA-125 blood test, have not found that either approach reduces how many women die of ovarian cancer.
Choosing whether to pursue a screening test is rarely simple, because not every test turns out to be helpful and most come with some downside. This applies even to people with a higher genetic or family risk of ovarian cancer: rather than a standardized screening program, this group is generally encouraged to work out an individualized monitoring plan with a clinician, since no screening approach — even in higher-risk individuals — has been proven to lower the chance of dying from the disease.
Doctors use the term risk factor for anything that makes a disease more likely, and protective factor for anything that makes it less likely. Bringing up personal and family history directly with a doctor is the recommended starting point for anyone wondering whether their own risk is above average.
Early Detection Challenges of Ovarian Cancer
Early detection of ovarian cancer is difficult because the disease often causes vague, nonspecific symptoms in its initial stages. Mild abdominal discomfort, bloating, or pelvic pressure are frequently mistaken for benign conditions, which can delay clinical evaluation.
Because there is no proven screening test, detecting ovarian cancer relies on careful evaluation of persistent or worsening abdominal and pelvic symptoms rather than a single finding. Clinical evaluation combines symptom patterns with individual risk factors such as age and family history, and targeted imaging and laboratory testing are used when suspicion arises.
Diagnostic Testing Methods for Ovarian Cancer
Diagnostic evaluation for ovarian cancer typically combines a pelvic exam, imaging, and a CA-125 blood test. These tools examine the ovaries and pelvic area and help guide next steps, but none of them can give a definitive “yes or no” answer for cancer on their own.
A biopsy — the removal of cells or tissue so a pathologist can examine them under a microscope — is what actually confirms a diagnosis of ovarian cancer. For ovarian cancer, tissue is usually obtained during surgery to remove the tumor, rather than through a separate outpatient biopsy procedure. Because of this, the path to a confirmed diagnosis is closely linked to surgical evaluation in a way that differs from some other cancers.
Imaging Techniques in the Detection of Ovarian Cancer
Pelvic imaging is central to evaluating a possible ovarian mass. Transvaginal ultrasound is typically the first imaging test used, since a probe placed in the vagina can closely examine the uterus, fallopian tubes, ovaries, and bladder. An abdominal ultrasound may also be used to form a broader picture of the pelvis and abdomen.
When findings raise concern for malignancy or when the extent of disease needs to be evaluated, additional imaging — including CT (computed tomography), MRI, or PET scans — may be used alongside pelvic exam and laboratory testing to help assess disease extent and guide staging and treatment planning, rather than to make the initial detection.
Role of Blood Tests and Laboratory Evaluation for Ovarian Cancer
Blood tests are mainly used as a supportive tool in the diagnostic process, most often through the CA-125 assay, which measures the level of CA-125 released into the bloodstream. A higher-than-normal CA-125 result can point toward ovarian cancer, but noncancerous conditions like endometriosis can raise it too, which is why the test on its own is not specific enough to serve as a reliable screening or stand-alone diagnostic tool.
Because of this limited specificity, laboratory results are interpreted alongside the pelvic exam and imaging findings rather than on their own. In practice, CA-125 testing is more often useful for monitoring disease status and treatment response once a diagnosis has been made than for detecting cancer in the first place.
Classification and Clinical Coding of Ovarian Cancer
The ovarian cancer ICD-10 classification system provides a standardized framework for documenting confirmed diagnoses across healthcare settings. These codes are applied only after diagnostic confirmation and support consistency in medical records, epidemiological analysis, and healthcare reporting.
While ICD-10 codes play an important role in health statistics, insurance documentation, and public health monitoring, they are not used for diagnosis or screening. Their role is administrative and analytical, organizing and communicating diagnostic outcomes after clinical evaluation and testing are already complete.
Disease Spread and Imaging Correlation in Ovarian Cancer
Ovarian cancer most often spreads within the abdominal cavity itself, a pattern sometimes described as intraperitoneal spread, where cancer cells settle onto the lining of the abdomen (the peritoneum) and the organs it covers. Staging descriptions capture this progression in steps: disease that has reached fatty tissue such as the omentum or nearby lymph-node groups outside the pelvis ranks as more advanced than disease still confined to the ovaries, while involvement of the liver or spleen surface, or spread to a distant site such as the lungs, marks the most advanced category.
Because imaging characteristics alone cannot establish malignancy, findings on ultrasound or other imaging are always interpreted together with the clinical exam, laboratory results, and, when indicated, tissue evaluation, to reach an accurate diagnosis and to understand how far the disease may have spread.
FAQs About Ovarian Cancer
What does ovarian cancer look like on ultrasound?
On ultrasound, a mass suspicious for ovarian cancer typically looks more complex than a simple, fluid-filled cyst. The image may show irregular solid areas, thickened walls, internal septations, or a mix of solid and fluid components, sometimes with increased blood flow on Doppler imaging. These features raise concern but are not diagnostic on their own, since similar appearances can occur with benign conditions, which is why ultrasound findings are interpreted together with a full clinical evaluation and additional testing.
Which way does ovarian cancer tend to spread?
Ovarian cancer typically grows outward from the ovary onto the peritoneum — the tissue lining the abdominal wall and covering the organs inside it — often reaching the fatty omentum in the process. With further progression, it may extend to lymph-node clusters positioned behind the peritoneum or onto the liver or spleen where they sit against the peritoneal cavity, and in the furthest-advanced cases it can turn up at distant locations, such as around the lungs or in lymph nodes beyond the abdomen.
Is there a blood test for ovarian cancer?
Blood testing plays a supporting role through the CA-125 assay, which measures a substance that can be elevated when ovarian cancer is present. However, CA-125 can also rise with unrelated, noncancerous conditions, so an elevated result is not used by itself to diagnose ovarian cancer — it is considered together with imaging and clinical findings.
Sources
